Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174121036> ?p ?o ?g. }
- W3174121036 endingPage "100967" @default.
- W3174121036 startingPage "100967" @default.
- W3174121036 abstract "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 19 (COVID-19), a respiratory infection that, starting from December 2019, has spread around the world in a few months, becoming a pandemic. The lack of initial knowledge on its management has led to a great effort in developing vaccines and in finding therapeutic weapons capable of improving the clinical outcome of the affected patients. In particular, the possible role of vitamin D status in the management of COVID-19 has been widely analysed, resulting in a great amount of data. This systematic review and meta-analysis aimed to assess whether hypovitaminosis D is a risk factor for developing SARS-CoV-2 infection and whether it affects the worsening of the clinical course of COVID-19.Data were extracted through extensive searches in the Pubmed, MEDLINE, Cochrane, Academic One Files, Google Scholar, and Scopus databases from December 2019 to January 2021, using the keywords: Vitamin D, 25 hydroxy Vitamin D, 25 hydroxycholecalciferol, cholecalciferol, COVID 19″, SARS-CoV-2″. We included observational cohort, cross-sectional, and case-control studies that evaluated differences in serum levels of 25‑hydroxy-cholecalciferol [25(OH)D] in patients who were positive or negative for SARS-CoV-2, in patients with mild or severe forms of COVID-19, and in patients who died or were discharged from the hospital. Finally, studies that evaluated the risk of developing severe illness or death in patients with vitamin D deficiency (VDD), defined as levels of 25(OH)D <20 ng/ml, were also included. We calculated the mean difference (MD) and the 95% confidence intervals (CI) for quantitative variables such as 25(OH)D levels in patients with or without SARS-CoV-2 infection, in those with mild vs. severe COVID-19, or those who have died vs. those who have been discharged. Instead, we calculated odds ratios and 95% CI for qualitative ones, such as the number of patients with severe illness/death in the presence of VDD vs. those with normal serum 25(OH)D levels. A p-value lower than 0.05 was considered statistically significant. The study was registered on PROSPERO (CRD42021241473).Out of 662 records, 30 articles met inclusion criteria and, therefore, were included in the meta-analysis. We found that the serum levels of 25(OH)D were significantly lower in patients with SARS-CoV-2 infection than in negative ones [MD -3.99 (-5.34, -2.64); p <0.00001; I2= 95%]. Furthermore, its levels were significantly lower in patients with severe disease [MD -6.88 (-9.74, -4.03); p <0.00001; I2=98%] and in those who died of COVID-19 [MD -8.01 (-12.50, -3.51); p = 0.0005; I2=86%]. Finally, patients with VDD had an increased risk of developing severe disease [OR 4.58 (2.24, 9.35); p <0.0001; I2=84%] but not a fatal outcome [OR 4.92 (0.83, 29.31); p = 0.08; I2=94%].This meta-analysis revealed a large heterogeneity of the studies included due to the different enrolment criteria of patient samples (age, body mass index, ethnicity, comorbidities), the country where they live, all factors influencing serum 25(OH)D levels, and the different criteria used to define the severity of COVID-19. Furthermore, the observational nature of these studies does not allow to establish a cause-effect relationship, even taking into account that 25(OH)D represents a marker of acute inflammation. Treatment with vitamin D might be considered for the primary prevention of SARS-CoV-2 infection and the management of patients with COVID-19. However, further intervention studies are needed to prove this hypothesis." @default.
- W3174121036 created "2021-07-05" @default.
- W3174121036 creator A5005824868 @default.
- W3174121036 creator A5010640509 @default.
- W3174121036 creator A5021384634 @default.
- W3174121036 creator A5034605711 @default.
- W3174121036 creator A5050080012 @default.
- W3174121036 creator A5061185015 @default.
- W3174121036 creator A5089438091 @default.
- W3174121036 creator A5091212489 @default.
- W3174121036 date "2021-07-01" @default.
- W3174121036 modified "2023-10-02" @default.
- W3174121036 title "Influence of 25-hydroxy-cholecalciferol levels on SARS-CoV-2 infection and COVID-19 severity: A systematic review and meta-analysis" @default.
- W3174121036 cites W1979423827 @default.
- W3174121036 cites W2000030095 @default.
- W3174121036 cites W2078961335 @default.
- W3174121036 cites W2153059487 @default.
- W3174121036 cites W2169205464 @default.
- W3174121036 cites W2170892587 @default.
- W3174121036 cites W2572633907 @default.
- W3174121036 cites W2588681363 @default.
- W3174121036 cites W2588906490 @default.
- W3174121036 cites W2616730536 @default.
- W3174121036 cites W2765383321 @default.
- W3174121036 cites W2766058165 @default.
- W3174121036 cites W2891732635 @default.
- W3174121036 cites W2913249953 @default.
- W3174121036 cites W2969563167 @default.
- W3174121036 cites W2998748948 @default.
- W3174121036 cites W3005178228 @default.
- W3174121036 cites W3012421327 @default.
- W3174121036 cites W3012690941 @default.
- W3174121036 cites W3016157077 @default.
- W3174121036 cites W3016692264 @default.
- W3174121036 cites W3017817496 @default.
- W3174121036 cites W3020313959 @default.
- W3174121036 cites W3020848235 @default.
- W3174121036 cites W3021179480 @default.
- W3174121036 cites W3022588744 @default.
- W3174121036 cites W3023458522 @default.
- W3174121036 cites W3023510226 @default.
- W3174121036 cites W3025649230 @default.
- W3174121036 cites W3030152549 @default.
- W3174121036 cites W3034164698 @default.
- W3174121036 cites W3036806031 @default.
- W3174121036 cites W3037163939 @default.
- W3174121036 cites W3037558495 @default.
- W3174121036 cites W3037748394 @default.
- W3174121036 cites W3040656307 @default.
- W3174121036 cites W3041319886 @default.
- W3174121036 cites W3044007210 @default.
- W3174121036 cites W3047725306 @default.
- W3174121036 cites W3049572366 @default.
- W3174121036 cites W3049660088 @default.
- W3174121036 cites W3049695144 @default.
- W3174121036 cites W3080192750 @default.
- W3174121036 cites W3081140618 @default.
- W3174121036 cites W3081154449 @default.
- W3174121036 cites W3081154908 @default.
- W3174121036 cites W3081594520 @default.
- W3174121036 cites W3084090627 @default.
- W3174121036 cites W3084230824 @default.
- W3174121036 cites W3085213571 @default.
- W3174121036 cites W3086048794 @default.
- W3174121036 cites W3086826118 @default.
- W3174121036 cites W3087554603 @default.
- W3174121036 cites W3088259748 @default.
- W3174121036 cites W3088561341 @default.
- W3174121036 cites W3092251879 @default.
- W3174121036 cites W3092723713 @default.
- W3174121036 cites W3092944659 @default.
- W3174121036 cites W3093262409 @default.
- W3174121036 cites W3094931890 @default.
- W3174121036 cites W3095756268 @default.
- W3174121036 cites W3096098401 @default.
- W3174121036 cites W3096188187 @default.
- W3174121036 cites W3099947806 @default.
- W3174121036 cites W3101675423 @default.
- W3174121036 cites W3103719306 @default.
- W3174121036 cites W3104089320 @default.
- W3174121036 cites W3105079777 @default.
- W3174121036 cites W3108187073 @default.
- W3174121036 cites W3111040995 @default.
- W3174121036 cites W3111873399 @default.
- W3174121036 cites W3111885761 @default.
- W3174121036 cites W3113279967 @default.
- W3174121036 cites W3131821293 @default.
- W3174121036 cites W3134947426 @default.
- W3174121036 cites W3137901083 @default.
- W3174121036 doi "https://doi.org/10.1016/j.eclinm.2021.100967" @default.
- W3174121036 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8215557" @default.
- W3174121036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34179737" @default.
- W3174121036 hasPublicationYear "2021" @default.
- W3174121036 type Work @default.
- W3174121036 sameAs 3174121036 @default.
- W3174121036 citedByCount "34" @default.
- W3174121036 countsByYear W31741210362021 @default.
- W3174121036 countsByYear W31741210362022 @default.